Stuart Lutzker
Co-Founder, President of Research & Development and DirectorDr. Stuart Lutzker, MD, PhD, is the Co-Founder, President of Research & Development since January 25, 2022 and Director since June 2021 at ArriVent Biopharma, Inc. Dr. Lutzker serves as Member of Scientific Advisory Board at Ambrx Biopharma Inc. Dr. Lutzker served as Member of Scientific Advisory Board at Aarvik Therapeutics, Inc until 2024. He has been Member of Scientific Advisory Board at Immune-Onc Therapeutics, Inc. since May 2021 and Ambrx, Inc. since June 2021. A pioneer of the biotech industry, Dr. Lutzker has extensive oncology drug discovery and development experience. He was the Head of Oncology, Early Clinical Development at Roche Holding AG. Dr. Lutzker served as Vice President of BioOncology Exploratory Clinical Development at Genentech, Inc. Dr. Lutzker has extensive drug development experience. Dr. Lutzker is an industry veteran with decades of oncology drug development and leadership experience. Most recently, Dr. Lutzker was Vice President of Oncology Early Clinical Development at Genentech from 2009 to 2021, where he led the early development of multiple now approved oncology drugs including Kadcyla®, Polivy®, Venclexta®, Cotellic® and Tecentriq®. Prior to Genentech, Dr. Lutzker was a medical oncologist and cancer researcher at the NCI-Designated Cancer Institute of New Jersey, where he divided his time between patient care and laboratory-based cancer research. Dr. Lutzker has also served as faculty for the ASCO/AACR Methods in Clinical Cancer Research Workshop in Vail, CO. Dr. Lutzker received his M.D./Ph.D. in Biochemistry from Columbia University College of Physicians and Surgeons. Following his residency and fellowship in Internal Medicine and Medical Oncology at Yale-New Haven Hospital, Dr. Lutzker completed post-doctoral research training in the Department of Molecular Biology at Princeton University.
Positions
- Company NameArriVent BioPharma, Inc.Stock CodeAVBPPositionCo-Founder, President of Research & Development and Director
